Revenue grew 19.22% YoY as operating margin fell for a third quarter
Expenses grew faster than revenue, while other income contributed 13.41% of pre-tax profit and cushioned reported earnings.
Filed 30 Jul 2026, 13:19 IST · Privi Speciality Chemicals Ltd (PRIVISCL)
Key takeaways
- Consolidated revenue rose +19.22% YoY, but expenses grew +20.43%, narrowing operating margin by 0.77 percentage points.
- Net profit increased +43.94% YoY, helped by a 2.18 percentage-point lower tax rate and interest costs falling 29.25%.
- Operating margin fell to 22.86% for a third straight quarter, but remained 4.14 percentage points above the 32-peer sector median.
Price around the results
Growth held up YoY, but Q1 lost sequential momentum
Consolidated revenue grew +19.22% YoY to Rs 666.22 cr, while operating profit rose only +15.30% as costs grew faster than sales. Sequentially, revenue fell -7.66% and operating profit declined -15.52%, showing a sharper drop in operating earnings than in sales. Net profit still grew +43.94% YoY, aided by lower interest and tax costs.
Faster cost growth squeezed the operating margin
Expenses rose +20.43% YoY against revenue growth of +19.22%, reducing operating margin by 0.77 percentage points to 22.86%. The sequential margin decline was wider at 2.12 percentage points because expenses fell -5.05%, less than the -7.66% fall in revenue. Other income accounted for 13.41% of pre-tax profit, so reported earnings had a material non-operating contribution. The tax rate fell by 2.18 percentage points YoY, while interest expense declined 29.25%, supporting net profit growth.
Margin has declined for three straight quarters
Operating margin has fallen from 26.82% in Q2FY26 to 25.03% in Q3FY26, 24.98% in Q4FY26 and 22.86% in Q1FY27. Even after that deterioration, Privi's margin was 4.14 percentage points above the 18.72% median for 32 reported Commodities-sector peers. The current quarter therefore combines a third consecutive sequential margin decline with an above-peer operating margin.
Management points to PRIGIV and specialty-molecule expansion
Management said the company is on track for Rs 5,000 crore of revenue and more than Rs 1,000 crore of EBITDA by FY29-30, with EBITDA margins expected to remain above 20%. The presentation said Privi and Givaudan have invested Rs 50 crore as equity in the PRIGIV project, which is under implementation. Management also said it is evaluating additional capex for high-value specialty molecules that could generate about Rs 100 crore or more in revenue. The company said more than 40 products are planned under PRIGIV and that it continues to focus R&D on new products and processes.
No post-results market move yet; past reactions skew negative
The results are too fresh for a post-results stock reaction. After its last eight results, the stock moved down seven times and up once, with a median absolute move of 1.4%. That history points to a generally negative reaction pattern, although the current quarter has not yet produced a reported move.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹666 cr | ₹722 cr | -7.66% | +19.22% |
| Other income | ₹15 cr | ₹4 cr | +263.64% | +69.08% |
| Expenses | ₹514 cr | ₹541 cr | -5.05% | +20.43% |
| Operating profit | ₹152 cr | ₹180 cr | -15.52% | +15.30% |
| Operating margin (%) | 22.86% | 24.98% | — | — |
| Interest | ₹17 cr | ₹18 cr | -8.27% | -29.25% |
| Depreciation | ₹37 cr | ₹36 cr | +2.41% | +3.18% |
| Profit before tax | ₹113 cr | ₹130 cr | -12.58% | +39.65% |
| Tax | ₹31 cr | ₹36 cr | -14.19% | +29.20% |
| Net profit | ₹83 cr | ₹94 cr | -11.98% | +43.94% |
| EPS (₹) | ₹21.56 | ₹23.99 | -10.13% | +36.03% |
Operating margin of 22.86% compares with a Commodities sector median of 18.72% across 32 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- The company is on track to achieve Rs 5,000 crore revenue and Rs 1,000 crore-plus EBITDA by FY29-30.
- EBITDA margins are expected to remain above 20%.
Expansion
- Privi and Givaudan invested Rs 50 crore as equity in the PRIGIV project, which is under implementation.
- The company is evaluating additional capex for high-value specialty molecules, with potential revenue of about Rs 100 crore or more.
New products
- More than 40 products are planned under PRIGIV.
New initiatives
- The company has proposed amalgamating Privi Fine Sciences and Privi Biotechnologies with Privi Speciality Chemicals.
- The company has a high R&D focus on developing new products and processes.
What to watch
- Whether operating margin recovers from 22.86% after its third straight quarterly decline.
- Whether expense growth falls below revenue growth after running at +20.43% YoY versus +19.22%.
- Updates on the PRIGIV project and its more than 40 planned products.